During the clinical trials, some patients received posaconazole up to 1600 mg/day with no adverse reactions noted that were different from the lower doses. In addition, accidental overdose was noted in one patient who took 1200 mg BID for 3 days. No related adverse reactions were noted by the investigator.

Posaconazole is not removed by hemodialysis.

Hypersensitivity

NOXAFIL is contraindicated in persons with known hypersensitivity to posaconazole, any component of NOXAFIL, or other azole antifungal agents.

Use with Sirolimus

NOXAFIL is contraindicated with sirolimus. Concomitant administration of NOXAFIL with sirolimus increases the sirolimus blood concentrations by approximately 9 fold and can result in sirolimus toxicity [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY].

QT Prolongation with Concomitant Use with CYP3A4 Substrates

NOXAFIL is contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of NOXAFIL with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and rare occurrences of torsades de pointes [see WARNINIGS AND PRECAUTIONS and DRUG INTERACTIONS].

HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4

Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY].

Use with Ergot Alkaloids

Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism [see DRUG INTERACTIONS].

Last reviewed on RxList: 6/29/2012
This monograph has been modified to include the generic and brand name in many instances.